Avexa Of Australia Seeks Investors As Phase III Trials Of HIV Drug End
This article was originally published in PharmAsia News
Executive Summary
Australia's Avexa says it is inviting investors to help it develop an HIV drug about to complete Phase III studies. Avexa CEO Julian Chick acknowledged his firm, which has no approved products and has never made a profit, is discussing with people about providing it with additional funds. Data from the final studies of its apricitabine HIV drug still remain to be analyzed, but Avexa expects to announce the results within six months. (Click here for more